Classify the transaction before evaluating the supplier. The following is a diligence framework, not a legal determination.
| Proposed arrangement | Relevant distinction | Evidence to require |
|---|---|---|
| Approved medicine purchased as clinic stock | Counterparty authorisation and the clinic’s actual purchasing, dispensing or administration role matter. | Exact product/presentation, seller identity, authorisation evidence and applicable traceability responsibilities. FDA has enforced authorised-trading-partner requirements against a medical spa. (fda.gov) |
| Approved medicine dispensed to a named patient | The clinic may facilitate access without owning the medicine. | Identify who receives the prescription, dispenses, charges the patient, ships and handles complaints; document responsibilities in the agreement. |
| Compounded medicine under 503A | The statute requires an identified patient/prescription framework and other conditions, including restrictions on routine or inordinate copying. | Product-specific legal analysis and, when relied upon, the prescriber’s significant-difference determination. (uscode.house.gov) |
| Compounded medicine under 503B | Patient-specific prescriptions are not universally required, but separate bulk-substance and copy restrictions apply. | Identify the starting material and establish each relevant statutory condition; do not infer eligibility from office-use capability. (uscode.house.gov) |
Can a clinic buy compounded GLP-1 for office use? Office stock and patient-labelled delivery to a clinic are different arrangements. FDA’s prescription guidance explains that section 503A distribution requires patient-specific prescriptions, while qualifying 503B outsourcing facilities can supply non-patient-specific office stock. That general 503B capability does not establish eligibility for bulk-compounded semaglutide or tirzepatide. FDA prescription and office-use guidance. (fda.gov)
Explore the table row by row
A working view of the research
Approved medicine purchased as clinic stock
- Relevant distinction
- Counterparty authorisation and the clinic’s actual purchasing, dispensing or administration role matter.
- Evidence to require
- Exact product/presentation, seller identity, authorisation evidence and applicable traceability responsibilities. FDA has enforced authorised-trading-partner requirements against a medical spa. (fda.gov)
Sources cited on this page
- fda.gov · Source 1 ↗https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/pure-indulgence-aesthetics-723267-04012026
- uscode.house.gov · Source 2 ↗https://uscode.house.gov/us/usc/119-120/t21/s353a/?utm_source=openai
- uscode.house.gov · Source 3 ↗https://uscode.house.gov/us/usc/119-136/t21/s353b/?utm_source=openai
- fda.gov · Source 4 ↗https://www.fda.gov/media/97347/download